Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis–an external quality assessment workshop
(2019) In Vox Sanguinis 114(4). p.386-393- Abstract
- Background and Objectives: Fetal RHD genotyping of cell-free fetal DNA from RhD-negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 28 laboratories. Materials and Methods: Aliquots of pooled maternal plasma were sent to each laboratory. One sample was positive, and the second sample was negative for fetal RHD, verified by pre-workshop testing using quantitative real-time PCR (qPCR) analysis of RHD exons 4, 5, 7 and 10. Plasma samples were shipped at room temperature. A reporting scheme was supplied for data collection, including... (More)
- Background and Objectives: Fetal RHD genotyping of cell-free fetal DNA from RhD-negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 28 laboratories. Materials and Methods: Aliquots of pooled maternal plasma were sent to each laboratory. One sample was positive, and the second sample was negative for fetal RHD, verified by pre-workshop testing using quantitative real-time PCR (qPCR) analysis of RHD exons 4, 5, 7 and 10. Plasma samples were shipped at room temperature. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. Different methodological approaches were used, all employing qPCR with a total of eight different combinations of RHD exon targets. The samples were tested blindly. Results: Fetal RHD genotyping was performed with no false-negative and no false-positive results. One inconclusive result was reported for the RHD-positive sample, and four inconclusive results were reported for the RHD-negative sample. All clinical conclusions were satisfactory. Conclusion: This external quality assessment workshop demonstrates that despite the different approaches taken to perform the clinical assays, fetal RHD genotyping is a reliable laboratory assay to guide targeted use of Rh prophylaxis in a clinical setting. © 2019 International Society of Blood Transfusion (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/6d239467-1634-47da-91cf-a767c8e6d969
- author
- Clausen, Frederik Banch and Barrett, Angela Natalie
- contributor
- Hellberg, Åsa
LU
and Olsson, Martin L
LU
- author collaboration
- organization
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cell-free fetal DNA, external quality assessment, fetal RHD genotyping, Rh prophylaxis, article, controlled study, exon, false positive result, female, fetus, genotype, human, human tissue, maternal plasma, prophylaxis, quality control, quantitative analysis, real time polymerase chain reaction, room temperature
- in
- Vox Sanguinis
- volume
- 114
- issue
- 4
- pages
- 386 - 393
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:85062510754
- pmid:30834546
- ISSN
- 1423-0410
- DOI
- 10.1111/vox.12768
- language
- English
- LU publication?
- yes
- id
- 6d239467-1634-47da-91cf-a767c8e6d969
- date added to LUP
- 2019-06-14 09:15:12
- date last changed
- 2022-04-26 01:24:37
@article{6d239467-1634-47da-91cf-a767c8e6d969,
abstract = {{Background and Objectives: Fetal RHD genotyping of cell-free fetal DNA from RhD-negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 28 laboratories. Materials and Methods: Aliquots of pooled maternal plasma were sent to each laboratory. One sample was positive, and the second sample was negative for fetal RHD, verified by pre-workshop testing using quantitative real-time PCR (qPCR) analysis of RHD exons 4, 5, 7 and 10. Plasma samples were shipped at room temperature. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. Different methodological approaches were used, all employing qPCR with a total of eight different combinations of RHD exon targets. The samples were tested blindly. Results: Fetal RHD genotyping was performed with no false-negative and no false-positive results. One inconclusive result was reported for the RHD-positive sample, and four inconclusive results were reported for the RHD-negative sample. All clinical conclusions were satisfactory. Conclusion: This external quality assessment workshop demonstrates that despite the different approaches taken to perform the clinical assays, fetal RHD genotyping is a reliable laboratory assay to guide targeted use of Rh prophylaxis in a clinical setting. © 2019 International Society of Blood Transfusion}},
author = {{Clausen, Frederik Banch and Barrett, Angela Natalie}},
issn = {{1423-0410}},
keywords = {{cell-free fetal DNA; external quality assessment; fetal RHD genotyping; Rh prophylaxis; article; controlled study; exon; false positive result; female; fetus; genotype; human; human tissue; maternal plasma; prophylaxis; quality control; quantitative analysis; real time polymerase chain reaction; room temperature}},
language = {{eng}},
number = {{4}},
pages = {{386--393}},
publisher = {{Wiley-Blackwell}},
series = {{Vox Sanguinis}},
title = {{Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis–an external quality assessment workshop}},
url = {{http://dx.doi.org/10.1111/vox.12768}},
doi = {{10.1111/vox.12768}},
volume = {{114}},
year = {{2019}},
}